Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency

Diabetes, Obesity and Metabolism

Volumn 13, Issue SUPPL. 1, 2011, Pages 133-143

  Farhy, L S ^a   Mccall, A L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Counterregulation; Diabetes mellitus; Feedback; Glucagon; Hypoglycaemia; Intrapancreatic network; Mathematical model

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCAGON RECEPTOR; INSULIN; PRAMLINTIDE; SOMATOSTATIN; VILDAGLIPTIN;

GLUCAGON RELEASE; HUMAN; HYPERGLUCAGONEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REVIEW;

EID: 79961180323     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01455.x     Document Type: Review

References (61)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
4. Cryer PE, Gerich JE. Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care 1983; 6: 95-99.
5. Gerich JE. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 1988; 37: 1608-1617.
6. Fukuda M, Tanaka A, Tahara Y et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81-88.
7. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171-173.
8. Hoffman RP, Arslanian S, Drash AL, Becker DJ. Impaired counterregulatory hormone responses to hypoglycemia in children and adolescents with new onset IDDM. J Pediatr Endocrinol 1994; 7: 235-244.
9. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724-733.
10. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
11. Cryer PE. Hypoglycemia the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-948.
12. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91: 819-828.
13. Gromada J, Franklin I, Wollheim CB. α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84-116.
14. Hirsch BR, Shamoon H. Defective epinephrine and growth hormone responses in type I diabetes are stimulus specific. Diabetes 1987; 36: 20-26.
15. Taborsky GJ Jr, Ahren B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 1998; 47: 995-1005.
16. Banarer S, McGregor VP, Cryer PE. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 2002; 51: 958-965.
17. Zhou H, Tran PO, Yang S et al. Regulation of alpha-cell function by the beta-cell during hypoglycemia in Wistar rats: the "switch-off" hypothesis. Diabetes 2004; 53: 1482-1487.
18. Hope KM, Tran PO, Zhou H, Oseid E, Leroy E, Robertson RP. Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis. Diabetes 2004; 53: 1488-1495.
19. Zhou H, Zhang T, Oseid E, Harmon J, Tonooka N, Robertson RP. Reversal of defective glucagon responses to hypoglycemia in insulin-dependent autoimmune diabetic BB rats. Endocrinology 2007; 148: 2863-2869.
20. Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP. Zinc, not insulin, regulates the rat α-cell response to hypoglycemia in vivo. Diabetes 2007; 56: 1107-1112.
21. Farhy LS, Du Z, Zeng Q et al. Amplification of pulsatile glucagon secretion by switch-off of α-cell suppressing signals in Streptozotocin (STZ)-treated rats. Am J Physiol Endocrinol Metab 2008; 295: E575-585.
22. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A 2010; 107: 16009-16012.
23. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60: 391-397.
24. Wang MY, Chen L, Clark GO et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A 2010; 107: 4813-4819.
25. Farhy LS, McCall AL. System-level control to optimize glucagon counterregulation by switch-off of alpha-cell suppressing signals in beta-cell deficiency. J Diabetes Sci Technol 2009; 3: 21-33.
26. Farhy LS, McCall AL. Pancreatic network control of glucagon secretion and counterregulation. Methods Enzymol 2009; 467: 547-581.
27. Farhy LS, McCall AL. Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action. J Diabetes Sci Technol 2010; 4: 1345-1356.
28. Kawai K, Unger RH. Inhibition of glucagon secretion by exogenous glucagon in the isolated, perfused dog pancreas. Diabetes 1982; 31: 512-515.
29. Stagner JI, Samols E, Bonner-Weir S. Beta-alpha-delta pancreatic islet cellular perfusion in dogs. Diabetes 1988; 37: 1715-1721.
30. Stagner JI, Samols E, Marks V. The anterograde and retrograde infusion of glucagon antibodies suggests that A cells are vascularly perfused before D cells within the rat islet. Diabetologia 1989; 32: 203-206.
31. Brunicardi FC, Kleinman R, Moldovan S et al. Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated per fused human pancreas. Pancreas 2001; 23: 302-308.
32. Epstein S, Berelowitz M, Bell NH. Pentagastrin and glucagon stimulate serum somatostatin-like immunoreactivity in man. J Clin Endocrinol Metab 1980; 51: 1227-1231.
33. Utsumi M, Makimura H, Ishihara K, Morita S, Baba S. Determination of immunoreactive somatostatin in rat plasma and responses to arginine, glucose and glucagon infusion. Diabetologia 1979; 17: 319-323.
34. Cejvan K, Coy DH, Efendic S. Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 2003; 52: 1176-1181.
35. Klaff LJ, Taborsky GJ Jr. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes 1987; 36: 592-596.
36. Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 2004; 52: 391-400.
37. Sumida Y, Shima T, Shirayama K, Misaki M, Miyaji K. Effects of hexoses and their derivatives on glucagon secretion from isolated perfused rat pancreas. Horm Metab Res 1994; 26: 222-225.
38. Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000; 8: 126-132.
39. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000; 141: 111-117.
40. Schuit FC, Derde MP, Pipeleers DG. Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 1989; 32: 207-212.
41. Kleinman R, Gingerich R, Ohning G et al. The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas. Int J Pancreatol 1995; 18: 51-57.
42. Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000; 43: 1012-1019.
43. Heise T, Heinemann T, Heller S et al. Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 2004; 53: 1227-1232.
44. Havel PJ, Ahren B. Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 1997; 46: 801-807.
45. Havel PJ, Taborsky GJ Jr. The contribution of the autonomic nervous system to changes of glucagon and insulin secretion during hypoglycemic stress. Endocr Rev 1989; 10: 332-350.
46. Brelje TC, Scharp DW, Sorenson RL. Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. Diabetes 1989; 38: 808-814.
47. Bolli GB, Fanelli CG. Physiology of glucose counterregulation to hypoglycemia. Endocr Metab Clin North Am 1999; 28: 467-493.
48. Taborsky GJ, Ahren B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 1998; 47: 995-1005.
49. Genter P, Berman N, Jacob M, Ipp E. Counterregulatory hormones oscillate during steady-state hypoglycemia. Am J Physiol 1998; 275: E821-829.
50. Grapengiesser E, Salehi A, Quader SS, Hellman B. Glucose induces glucagon release pulses antisynchronous with insulin and sensitive to purinoceptors inhibition. Endocrinology 2006; 147: 3472-3477.
51. Jaspan JB, Lever E, Polonsky KS, Van Cauter E. In vivo pulsatility of pancreatic islet peptides. Am J Physiol 1986; 251: E215-226.
52. Salehi A, Quader SS, Grapengiesser E, Hellman B. Pulses of somatostatin release are slightly delayed compared with insulin and antisynchronous to glucagon, Regul Pept 2007; 144: 43-49.
53. Farhy LS. Modeling of oscillations in endocrine networks with feedback. Methods Enzymol 2004; 384: 54-81.
54. Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data. Anal Biochem 2008; 381: 8-17.
55. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
56. Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403.
57. Ahrén B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
58. McCall AL, Cox DJ, Crean J, Gloster MA, Kovatchev BP. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 2006; 8: 644-653.
59. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277: E283-290.
60. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes 1971; 20: 834-838.
61. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010; 2: 27ra27.